Yeztugo® (lenacapavir)
for Human Immunodeficiency Virus

Yeztugo (lenacapavir) is a capsid inhibitor used for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 in adults and adolescents weighing at least 35 kg (77 lbs). It binds to HIV-1 capsid protein subunits, disrupting multiple stages of the viral lifecycle. Yeztugo blocks nuclear import of proviral DNA, interferes with virus assembly and release by reducing capsid production, and prevents proper capsid core formation through malformed assembly.

Heart
Medication Guide Icon Medication Guide
Patient Website Icon Patient Website
Efficacy Data Icon Efficacy Data
New Articles Icon New Articles
Savings and Support Icon Savings and Support
Company MD Payments Icon Company MD Payments
Clinical Trials Icon Clinical Trials
Adverse Event Report Icon Adverse Event Report
Other top medicines used to treat Human Immunodeficiency Virus - HIV